Medigene AG buy melinda
Start price
25.10.18
/
50%
€9.97
Target price
02.11.18
€11.10
Performance (%)
11.33%
End price
02.11.18
€11.10
Summary
This prediction ended on 02.11.18 with a price of €11.10. The prediction had a final performance of 11.33%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Medigene AG | -18.622% | -18.622% | -10.141% | -58.839% |
| iShares Core DAX® | 1.051% | -1.833% | 12.822% | 15.392% |
| iShares Nasdaq 100 | -0.547% | -3.738% | 40.625% | 42.396% |
| iShares Nikkei 225® | -1.778% | -8.115% | 16.092% | 0.891% |
| iShares S&P 500 | 0.002% | -2.226% | 28.387% | 41.095% |
According to melinda what are the pros and cons of Medigene AG for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Medigene AG diskutieren
SecteurRecherche biotechnologique et médicale Agenda 25/10 Présentation
MediGene AG is a biotechnology company, which engages in developing innovative, complementary treatment platforms that target various types and stages of cancer.
It focuses on the development of personalized T-cell based immunotherapies.
It operates through the Immunotherapies and Other products segments.
The company was founded by Ernst Ludwig Winnacker and Horst Domdey in June 1994 and is headquartered in Martinsried, Germany.
Nombre d'employés : 96 personnes.
Stopped prediction by melinda for Medigene AG
Medigene AG
Start price
Target price
Perf. (%)
€3.35
16.03.20
16.03.20
€4.50
04.11.21
04.11.21
6.12%
05.11.21
05.11.21
Could be worthwhile Investment >10% per year
Medigene AG
Start price
Target price
Perf. (%)
€6.72
03.11.10
03.11.10
€12.00
03.05.11
03.05.11
20.18%
03.05.11
03.05.11
Could be worthwhile Investment >10% per year